查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470504

旅行疫苗市場：按類型、疾病分類 - 2024-2030 年全球預測

Travel Vaccines Market by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines), Disease (DPT, Hepatitis A, Hepatitis B) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年旅行疫苗市場規模為82.6億美元，預計2024年將達到90.9億美元，2030年將達到161.8億美元，複合年成長率為10.06%。

旅行疫苗市場包括根據特定地區的疾病風險暴露向國際旅客推薦或要求的免疫接種的製造、分銷和管理。旅行疫苗市場的持續成長主要是由於國際旅行的增加、對疫苗可預防疾病的認知不斷提高以及政府旅行法規要求入境時必須接種某些疫苗。此外，全球旅遊業的擴張和國際旅客積極的健康措施正在刺激對旅行疫苗的需求。疫苗儲存和穩定性方面的技術進步使疫苗的供應和分發範圍更廣，從而促進了市場成長。影響旅行疫苗市場成長的主要挑戰包括與疫苗開發相關的高成本以及導致核准時間更長的嚴格監管要求。此外，疫苗保存期限有限、低溫運輸物流要求、某些旅行者群體對疫苗的猶豫等進一步阻礙了市場成長。新興市場開拓包括開發針對不斷變化的感染疾病威脅的疫苗以及擴大現有的旅行疫苗組合以包括被忽視的熱帶疾病。疫苗研發方面官民合作關係關係的增加，以及用於個人化旅行健康建議和疫苗提醒的數位健康技術的引入，都預示著行業擴張的強勁前景。

主要市場統計
基準年[2023] 82.6億美元
預測年份 [2024] 90.9億美元
預測年份 [2030] 161.8億美元
複合年成長率（%） 10.06%

類型：誘導免疫反應的 DNA 疫苗的進展

減毒疫苗是透過削弱引起疾病的病原體而製成的。減毒疫苗能夠非常有效地產生強烈、持久的免疫反應。結合疫苗旨在對抗具有多醣體外殼的細菌。透過將免疫系統可以辨識的微生物抗原或類毒素附著在多醣上，結合疫苗可以改善人體對細菌的免疫反應。 DNA 疫苗是一種尖端方法，涉及直接注射基因工程 DNA，使細胞產生抗原並誘導免疫反應。惰性疫苗使用殺死的引起疾病的細菌，比活病毒疫苗更安全，對於免疫力較弱的人特別有效，但它們不能保持免疫力，可能需要多次接種疫苗才能實現這一點。重組載體疫苗利用病毒或細菌將微生物 DNA 引入人類細胞，設計複雜，可誘發強烈的免疫反應。次單位疫苗是一種只含有必需抗原而不含有微生物所有其他分子的疫苗，副作用風險較低，但可能需要佐劑來增強免疫反應。類毒素疫苗用於對抗在體內產生毒素的細菌，並透過去活化細菌產生的毒素來誘發免疫反應。

疾病：旅行者需接種肝炎疫苗

儘管主要建議幼兒接種百白破疫苗，但建議前往白喉和百日咳仍然流行的地區的成年人接種加強劑。建議大多數旅客攜帶甲型肝炎，尤其是前往甲型肝炎感染率高的地區（例如亞洲、非洲、中美洲和南美洲）的旅客。特別建議長期前往日本腦炎流行地區（例如亞洲農村地區）的旅客。旱季前往撒哈拉以南非洲的旅客和沙烏地阿拉伯的朝覲者必須接種腦膜炎雙球菌疫苗。建議在有狂犬病風險的地區進行戶外活動的旅客或前往難以獲得醫療設施的偏遠地區的旅客接種狂犬病疫苗。水痘（水痘）對於沒有免疫力的旅客來說是必須的，尤其是年輕人和相關人員。黃熱病對於前往非洲和南美洲流行地區的旅客來說很重要。

區域洞察

在美洲，美國和加拿大是旅行疫苗的重要市場。由於完善的醫療保健系統以及前往存在疫苗可預防疾病的地區的頻繁旅行，歐盟 (EU) 呈現出強勁的旅遊疫苗市場。歐盟擁有精簡的法律規範，使其成為引入新疫苗的合適環境。中東和非洲地區是旅遊疫苗的活躍地區，由於波灣合作理事會國家的旅行和醫療投資增加，需求不斷成長。亞太地區的旅行疫苗市場正在快速成長，其中中國、日本和印度引領了市場擴張。特別是中國和印度正大力投資疫苗研發，旨在實現疫苗生產自給自足。日本市場的特點是消費者意識高、疫苗技術先進，並得到政府主導的疫苗接種宣傳活動的支持。

FPNV定位矩陣

FPNV 定位矩陣對於評估旅遊疫苗市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對旅行疫苗市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動和突破性產品開發的智力見解。

本報告解決了以下關鍵問題：

1. 旅行疫苗市場規模及預測是多少？

2.在旅行疫苗市場預測期內，我們應該考慮投資哪些產品與應用？

3. 旅行疫苗市場的技術趨勢和法規結構是什麼？

4.旅行疫苗市場主要供應商的市場佔有率是多少？

5. 進入旅遊疫苗市場的合適業態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 國際觀光日益普及
      • 感染疾病的傳播和聯合疫苗的開發
      • 低溫運輸倉儲基礎設施的最新投資和改進
    • 抑制因素
      • 旅客認知度低
    • 機會
      • 新疫苗技術的創新與進步
      • 政府和組織為免疫和疫苗開發提供的資金和努力
    • 任務
      • 疫苗處理和儲存問題
  • 市場區隔分析
    • 類型：引發免疫反應的 DNA 疫苗的進展
    • 疾病：優先考慮旅行者的肝炎疫苗需求
  • 市場趨勢分析
  • 俄羅斯和烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章 旅行疫苗市場：依類型

  • 介紹
  • 減毒疫苗
  • 結合疫苗
  • DNA疫苗
  • 惰性疫苗
  • 重組載體疫苗
  • 次單位疫苗
  • 類毒素疫苗

第7章 旅行疫苗市場：依疾病分類

  • 介紹
  • 二氧化矽
  • 甲型肝炎
  • B型肝炎
  • 日本腦炎
  • 麻疹和腮腺炎
  • 腦膜炎奈瑟菌
  • 狂犬病
  • 傷寒
  • 水痘
  • 黃熱病

第8章美洲旅行疫苗市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太旅行疫苗市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲旅行疫苗市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析

第12章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-0316851957A3

[192 Pages Report] The Travel Vaccines Market size was estimated at USD 8.26 billion in 2023 and expected to reach USD 9.09 billion in 2024, at a CAGR 10.06% to reach USD 16.18 billion by 2030.

The travel vaccines market encompasses the production, distribution, and administration of immunizations recommended or required for international travelers based on specific regional disease risk exposures. The ongoing growth in the travel vaccines market is primarily driven by increased international travel, rising awareness about vaccine-preventable diseases, and governmental travel regulations mandating certain vaccines for entry. Additionally, the expansion of the global tourism industry and proactive health measures by international travelers fuel the demand for travel vaccines. Technological advancements in vaccine storage and stability contribute to market growth by enabling wider vaccine accessibility and distribution. The major challenges affecting the growth of the travel vaccines market include high costs associated with vaccine development and strict regulatory requirements leading to prolonged approval times. Additionally, the limited shelf life of vaccines, cold chain logistics requirements, and vaccine hesitancy among specific traveler demographics further impede market growth. Emerging market opportunities include developing vaccines against evolving infectious disease threats and expanding the existing travel vaccine portfolio to include neglected tropical diseases. An increase in public-private partnerships for vaccine research and development and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders represent significant prospects for industry expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 8.26 billion
Estimated Year [2024] USD 9.09 billion
Forecast Year [2030] USD 16.18 billion
CAGR (%) 10.06%

Type: Advancements in DNA vaccines to induce immune response

Attenuated vaccines utilize a weakened form of the germ that causes a disease. Attenuated vaccines are highly effective in eliciting strong and long-lasting immune responses. Conjugate vaccines are designed to combat bacteria with polysaccharide outer coatings. By linking antigens or toxoids from a microbe that the immune system can recognize to the polysaccharides, conjugate vaccines improve the body's immune response to the bacterium. DNA vaccines represent a cutting-edge approach by directly injecting genetically engineered DNA so cells can produce an antigen and induce an immune response. Inactive vaccines use the killed version of the germ that causes a disease and are safer than live vaccines, especially for people with weakened immune systems, but may require multiple doses to maintain immunity. Recombinant vector vaccines use a virus or a bacterium to introduce microbial DNA to body cells and are sophisticated in design and capable of inducing strong immune responses. Subunit vaccines include only the essential antigens and not all other molecules of the microbe and have a lower risk of side effects but may require adjuvants to enhance the immune response. Toxoid vaccines are used against bacteria that produce toxins in the body and are made by inactivating the toxins produced by the bacteria, which in turn induces an immune response.

Disease: Need based preference for hepatitis vaccines among travelers

DPT vaccines are primarily recommended for young children, but booster shots are advised for adults traveling to areas where diphtheria and pertussis (whooping cough) are still prevalent. Hepatitis is recommended for most travelers, especially those visiting regions with higher rates of Hepatitis A infection such as Asia, Africa, and Central and South America. Japanese encephalitis is advised for travelers staying for extended periods in endemic areas, especially in rural Asia. The meningococcal vaccine is essential for travelers to sub-Saharan Africa during the dry season and for pilgrims to the Hajj in Saudi Arabia. Rabies vaccine is recommended for travelers involved in outdoor activities in areas where rabies is a risk or for those traveling to remote locations where medical care is difficult to access. Varicella (Chickenpox) is essential for non-immune travelers, particularly young adults and healthcare professionals. Yellow fever is critical for travelers to endemic regions in Africa and South America.

Regional Insights

In the Americas, the United States and Canada represent significant markets for travel vaccines, driven by high outbound travel rates and robust healthcare infrastructure. Consumer behavior shows a high degree of awareness and preparedness for travel health, leading to a steadfast demand for vaccines against diseases such as Yellow Fever, Typhoid, and Hepatitis A and B. The European Union exhibits a robust travel vaccine market due to well-established healthcare systems and high travel frequency to regions with vaccine-preventable diseases. The EU's streamlined regulatory framework fosters a conducive environment for introducing new vaccines. The Middle East & Africa region presents a varied landscape for travel vaccines, with the Gulf Cooperation Council countries showing growing demand due to increasing travel and healthcare investments. The Asia Pacific region is witnessing rapid growth in the travel vaccine market, with China, Japan, and India leading the way for market expansion. Notably, China and India invest heavily in vaccine R&D to become self-sufficient in vaccine production. Japan's market is distinguished by high consumer awareness and advanced vaccine technology, supported by government-led immunization campaigns.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Travel Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Travel Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, Biological E Limited, Cadila Pharmaceuticals Limited, CSL Limited, Dano Vaccines & Biologicals Private Limited, Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Indian Immunologicals Ltd., Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Attenuated Vaccines
    • Conjugate Vaccines
    • DNA Vaccines
    • Inactive Vaccines
    • Recombinant Vector Vaccines
    • Subunit Vaccines
    • Toxoid Vaccines
  • Disease
    • DPT
    • Hepatitis A
    • Hepatitis B
    • Japanese Encephalitis
    • Measles and Mumps
    • Meningococcal
    • Rabies
    • Typhoid
    • Varicella
    • Yellow Fever
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Travel Vaccines Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Travel Vaccines Market?

3. What are the technology trends and regulatory frameworks in the Travel Vaccines Market?

4. What is the market share of the leading vendors in the Travel Vaccines Market?

5. Which modes and strategic moves are suitable for entering the Travel Vaccines Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Popularity of International Tourism
      • 5.1.1.2. Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
      • 5.1.1.3. Recent Investments and Improvement in Cold Chain Storage Infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Awareness Amongst Travelers
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in Novel Vaccine Technologies and Advancements
      • 5.1.3.2. Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
    • 5.1.4. Challenges
      • 5.1.4.1. Issues Related to Vaccine Handling and Storage
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Advancements in DNA vaccines to induce immune response
    • 5.2.2. Disease: Need based preference for hepatitis vaccines among travelers
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Travel Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccines
  • 6.3. Conjugate Vaccines
  • 6.4. DNA Vaccines
  • 6.5. Inactive Vaccines
  • 6.6. Recombinant Vector Vaccines
  • 6.7. Subunit Vaccines
  • 6.8. Toxoid Vaccines

7. Travel Vaccines Market, by Disease

  • 7.1. Introduction
  • 7.2. DPT
  • 7.3. Hepatitis A
  • 7.4. Hepatitis B
  • 7.5. Japanese Encephalitis
  • 7.6. Measles and Mumps
  • 7.7. Meningococcal
  • 7.8. Rabies
  • 7.9. Typhoid
  • 7.10. Varicella
  • 7.11. Yellow Fever

8. Americas Travel Vaccines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Travel Vaccines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Travel Vaccines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
    • 11.3.2. FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
    • 11.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. TRAVEL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. TRAVEL VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. TRAVEL VACCINES MARKET DYNAMICS
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ATTENUATED VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ATTENUATED VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RECOMBINANT VECTOR VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RECOMBINANT VECTOR VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DPT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DPT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL TRAVEL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL TRAVEL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MEASLES AND MUMPS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MEASLES AND MUMPS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. CANADA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 62. CANADA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 87. INDIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. INDIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 91. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. INDONESIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 94. INDONESIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 95. JAPAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. JAPAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. JAPAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 98. JAPAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 99. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 102. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 106. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 107. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 110. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 114. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 115. TAIWAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. TAIWAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. TAIWAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 118. TAIWAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 119. THAILAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. THAILAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. THAILAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 122. THAILAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 123. VIETNAM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. VIETNAM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. VIETNAM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 126. VIETNAM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 133. DENMARK TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. DENMARK TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. DENMARK TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 136. DENMARK TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 137. EGYPT TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. EGYPT TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. EGYPT TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 140. EGYPT TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 141. FINLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. FINLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. FINLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 144. FINLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 145. FRANCE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. FRANCE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. FRANCE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 148. FRANCE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 149. GERMANY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. GERMANY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. GERMANY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 152. GERMANY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 153. ISRAEL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. ISRAEL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. ISRAEL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 156. ISRAEL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 157. ITALY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. ITALY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. ITALY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 160. ITALY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 161. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 164. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 165. NIGERIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. NIGERIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. NIGERIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 168. NIGERIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 169. NORWAY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. NORWAY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. NORWAY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 172. NORWAY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 173. POLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. POLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. POLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 176. POLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 177. QATAR TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. QATAR TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. QATAR TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 180. QATAR TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 181. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. RUSSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 184. RUSSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 185. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 188. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 189. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 192. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 193. SPAIN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. SPAIN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. SPAIN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 196. SPAIN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 197. SWEDEN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. SWEDEN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. SWEDEN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 200. SWEDEN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 201. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 204. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 205. TURKEY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. TURKEY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. TURKEY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 208. TURKEY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 209. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 212. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 213. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 216. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 217. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 218. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023